Medical DeviceNews

Truenat test kit gets DCGI approval for Nipah diagnosis

This is the first kit in India to receive regulatory approval to conduct tests for Nipah

Truenat, an innovative point of care Real-Time PCR platform manufactured by Goa-based Molbio Diagnostics, has received Emergency Use Authorisation by the DCGI for Nipah test. This is the first kit in India to receive regulatory approval to conduct tests for Nipah.

“Truenat is the first platform to be authorised by the DGCI for Nipah virus testing. We are proud to support our country in fighting Nipah Virus,” said Sriram Natarajan, Director and CEO, Molbio Diagnostics.

“The R&D work on the Truenat test for Nipah virus was first started in 2018 in collaboration with the National Institute of Virology, Pune (ICMR) to enable the detection of the infectious virus during outbreak situations. The ability to quickly deploy the platform to the point of need and the rapid testing capability makes it a powerful tool in diagnosis and containment of the Nipah Virus. This collaboration with NIV allows us to react quickly in times of need such emergencies,” said Dr Chandrasekhar Nair, Director & CTO of Molbio Diagnostics.

Truenat is a truly indigenous portable, battery-operated, IoT-enabled point of care RT-PCR platform developed and manufactured in India by Molbio. The platform can test for nearly 30 diseases, and results take less than an hour. 

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close